S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NASDAQ:ZFGNZafgen Stock Price, Forecast & News

$10.50
0.00 (0.00 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.47
Now: $10.50
$10.92
50-Day Range
$0.99
MA: $11.47
$14.04
52-Week Range
$0.62
Now: $10.50
$2.76
Volume12,358 shs
Average Volume360,199 shs
Market Capitalization$393.44 million
P/E RatioN/A
Dividend YieldN/A
Beta0.27
Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Read More
Zafgen logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.92 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZFGN
CUSIPN/A
Phone617-622-4003

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.35 per share

Profitability

Net Income$-45,410,000.00

Miscellaneous

Employees38
Market Cap$393.44 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable
$10.50
0.00 (0.00 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZFGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zafgen (NASDAQ:ZFGN) Frequently Asked Questions

How has Zafgen's stock been impacted by COVID-19 (Coronavirus)?

Zafgen's stock was trading at $0.8501 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZFGN stock has increased by 1,135.1% and is now trading at $10.50.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Zafgen?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Zafgen
.

When is Zafgen's next earnings date?

Zafgen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Zafgen
.

How were Zafgen's earnings last quarter?

Zafgen Inc (NASDAQ:ZFGN) released its quarterly earnings data on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.19).
View Zafgen's earnings history
.

What price target have analysts set for ZFGN?

3 Wall Street analysts have issued 12-month price targets for Zafgen's shares. Their forecasts range from $0.78 to $0.78. On average, they expect Zafgen's stock price to reach $0.78 in the next twelve months. This suggests that the stock has a possible downside of 92.6%.
View analysts' price targets for Zafgen
.

Has Zafgen been receiving favorable news coverage?

Headlines about ZFGN stock have trended neutral on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Zafgen earned a news impact score of 0.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Zafgen
.

Are investors shorting Zafgen?

Zafgen saw a increase in short interest in January. As of January 15th, there was short interest totaling 823,200 shares, an increase of 58.1% from the December 31st total of 520,800 shares. Based on an average daily volume of 673,400 shares, the days-to-cover ratio is presently 1.2 days. Approximately 2.5% of the shares of the company are short sold.
View Zafgen's Short Interest
.

Who are some of Zafgen's key competitors?

What other stocks do shareholders of Zafgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), SCYNEXIS (SCYX), Endologix (ELGX), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), BlackRock (BLK), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Fate Therapeutics (FATE) and Pfizer (PFE).

Who are Zafgen's key executives?

Zafgen's management team includes the following people:
  • Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)
  • Ms. Patricia L. Allen, Chief Financial Officer (Age 57)
  • Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)
  • Dr. James E. Vath, Head of Discovery & Devel. (Age 58)
  • Mr. Brian P. McVeigh, Chief Bus. Officer (Age 46)

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

How do I buy shares of Zafgen?

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zafgen's stock price today?

One share of ZFGN stock can currently be purchased for approximately $10.50.

How big of a company is Zafgen?

Zafgen has a market capitalization of $393.44 million. The biopharmaceutical company earns $-45,410,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Zafgen employs 38 workers across the globe.

What is Zafgen's official website?

The official website for Zafgen is www.zafgen.com.

How can I contact Zafgen?

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.